Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies

Achieving undetectable MRD (U-MRD) status after chemoimmunotherapy predicts longer progression-free and overall survival. The predictive factors and timing of relapse in patients with U-MRD and value of interim MRD analysis are ill-defined. This was a prospective study of 289 patients with CLL treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Philip A., Peterson, Christine B., Strati, Paolo, Jorgensen, Jeff, Keating, Michael J., O’Brien, Susan M., Ferrajoli, Alessandra, Burger, Jan A., Estrov, Zeev, Jain, Nitin, Kadia, Tapan M., Borthakur, Gautam, DiNardo, Courtney D., Daver, Naval, Jabbour, Elias, Wierda, William G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192870/
https://www.ncbi.nlm.nih.gov/pubmed/29769624
http://dx.doi.org/10.1038/s41375-018-0132-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192870/
https://www.ncbi.nlm.nih.gov/pubmed/29769624
http://dx.doi.org/10.1038/s41375-018-0132-y

Ejemplares similares